Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Humacyte Inc (HUMA)

Humacyte Inc (HUMA)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 298,011
  • Shares Outstanding, K 103,118
  • Annual Sales, $ 1,260 K
  • Annual Income, $ -26,480 K
  • 60-Month Beta 1.31
  • Price/Sales 115.51
  • Price/Cash Flow N/A
  • Price/Book 2.28
Trade HUMA with:

Options Overview Details

View History
  • Implied Volatility 83.64% ( -103.96%)
  • Historical Volatility 71.81%
  • IV Percentile 13%
  • IV Rank 5.39%
  • IV High 774.35% on 01/09/23
  • IV Low 44.31% on 01/20/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1
  • Volume Avg (30-Day) 78
  • Put/Call OI Ratio 0.12
  • Today's Open Interest 3,733
  • Open Int (30-Day) 3,297

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/22
See More
  • Average Estimate -0.23
  • Number of Estimates 2
  • High Estimate -0.22
  • Low Estimate -0.25
  • Prior Year -0.22
  • Growth Rate Est. (year over year) -4.55%

Price Performance

See More
Period Period Low Period High Performance
1-Month
2.06 +49.32%
on 01/03/23
3.29 -6.38%
on 02/02/23
+0.97 (+45.97%)
since 12/30/22
3-Month
1.96 +57.14%
on 12/30/22
3.50 -12.00%
on 11/07/22
-0.39 (-11.24%)
since 11/02/22
52-Week
1.96 +57.14%
on 12/30/22
8.04 -61.69%
on 04/21/22
-1.95 (-38.77%)
since 02/02/22

Most Recent Stories

More News
Alpha Healthcare Acquisition Corp. III Announces Merger with Carmell Therapeutics, a Phase 2 Stage Biotechnology Platform Company Developing Allogeneic Plasma-based Biomaterials for Bone and Soft Tissue Healing Indications

Alpha Healthcare Acquisition Corp. III (Nasdaq: ALPA) (“ALPA”), a special purpose acquisition company led by Mr. Rajiv Shukla, today announced the execution of a definitive business combination agreement...

ALPA : 10.03 (-0.20%)
DMTK : 5.52 (unch)
HUMA : 3.08 (+6.57%)
Humacyte, Inc. (HUMA) Reports Q3 Loss, Misses Revenue Estimates

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -19.05% and 88.08%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

HUMA : 3.08 (+6.57%)
SYRS : 5.12 (-3.76%)
Prometheus Biosciences, Inc. (RXDX) Reports Q3 Loss, Tops Revenue Estimates

Prometheus Biosciences, Inc. (RXDX) delivered earnings and revenue surprises of -1.12% and 26.37%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the...

RXDX : 108.43 (-1.13%)
HUMA : 3.08 (+6.57%)
Halozyme Therapeutics (HALO) Surpasses Q3 Earnings and Revenue Estimates

Halozyme Therapeutics (HALO) delivered earnings and revenue surprises of 42.31% and 11.23%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?...

HALO : 52.87 (+1.34%)
HUMA : 3.08 (+6.57%)
Wall Street Analysts See an 85% Upside in Humacyte, Inc. (HUMA): Can the Stock Really Move This High?

The consensus price target hints at an 84.8% upside potential for Humacyte, Inc. (HUMA). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate...

HUMA : 3.08 (+6.57%)
Humacyte to Present Second Quarter 2022 Financial Results and Provide Recent Corporate Update on August 12, 2022

DURHAM, N.C., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally...

HUMA : 3.08 (+6.57%)
Humacyte Preclinical Data on Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting (CABG) Presented at American Heart Association Meeting

-- Preclinical model data expected to support development of small diameter HAV to treat patients with coronary artery disease-- -- Small-diameter HAV...

HUMA : 3.08 (+6.57%)
Humacyte Hosting Key Opinion Leader Webinar on Human Acellular Vessels™ in the Treatment of Vascular Trauma

Thursday, July 14, 2022 @ 11:30 a.m. ET...

HUMA : 3.08 (+6.57%)
Humacyte Expands Board of Directors with Appointment of Diane Seimetz, Ph.D.

Industry leader brings deep expertise in international drug development, strategic leadership, and corporate partnering for biopharmaceutical companies...

HUMA : 3.08 (+6.57%)
Humacyte Provides Update on Patients Treated at Front-Line Hospitals in Ukraine with the Human Acellular Vessel™ (HAV™) for Repair of Vascular Trauma Injuries

-- Successful first two HAV implantations in wounded Ukrainian citizens -- HAVs were provided under Humacyte’s initiative to assist Ukraine humanitarian...

HUMA : 3.08 (+6.57%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 40% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Humacyte Inc. is a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale. Humacyte Inc., formerly known as Alpha Healthcare Acquisition Corp., is based in DURHAM, N.C.

See More

Key Turning Points

3rd Resistance Point 3.60
2nd Resistance Point 3.45
1st Resistance Point 3.26
Last Price 3.08
1st Support Level 2.92
2nd Support Level 2.77
3rd Support Level 2.58

See More

52-Week High 8.04
Fibonacci 61.8% 5.72
Fibonacci 50% 5.00
Fibonacci 38.2% 4.28
Last Price 3.08
52-Week Low 1.96

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar